AHK-Cu vs Sermorelin
Well Studied vs Well Studied
synergistic Mechanism-based · 47% AHK-Cu and Sermorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
AHK-Cu Sermorelin
Weight 416.9 Da 3,358 Da
Half-life Not established 10-12 minutes
Chain 3 amino acids 29 amino acids
Type Copper tripeptide complex GHRH analog
Key Benefits
AHK-Cu
01 Hair follicle elongation stimulation
02 Dermal papilla cell proliferation
03 VEGF upregulation for improved scalp circulation
04 TGF-β1 reduction (counters DHT effects)
05 Anti-apoptotic protection for follicles
06 Collagen synthesis support
07 Convenient topical application
08 Fibroblast activation for skin regeneration
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
AHK-Cu
0.5-1% topical solution/serum / Once or twice daily application
Mesotherapy - Scalp (Practitioner) 0.1-0.5 mg per injection site Weekly sessions
Research Protocol 1-5 mg 2-3 times weekly
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
AHK-Cu
Generally well-tolerated with excellent safety profile in topical applications
Rare scalp irritation (patch test recommended)
Potential for mild redness on sensitive skin
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Not for use on broken or infected skin
Avoid eye area - may cause irritation
Do not use if allergic to copper or peptides
Not recommended during acute skin infections
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
AHK-Cu Sermorelin
Status Well Studied Well Studied
References 4 studies 5 studies
Latest March 2025 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.